deltatrials
Terminated PHASE3 INTERVENTIONAL 2-arm NCT02616146

Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring and Levonorgestrel-Ethinyl Estradiol Combined Oral Contraceptive in Adult Women at Risk for Pregnancy (MK-8342B-062)

A Phase 3, Randomized, Active-Comparator Controlled Clinical Trial to Study the Contraceptive Efficacy and Safety of the MK-8342B (Etonogestrel + 17β-Estradiol) Vaginal Ring and the Levonorgestrel-Ethinyl Estradiol (LNG-EE) 150/30 μg Combined Oral Contraceptive (COC) in Healthy Women 18 Years of Age and Older, at Risk for Pregnancy.

Sponsor: Organon and Co

Conditions Contraception
Updated 13 times since 2017 Last updated: May 8, 2024 Started: Dec 1, 2015 Primary completion: Oct 6, 2016 Completion: Oct 6, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study terminated by Sponsor as a result of a business decision to discontinue the development program for MK-8342B for reasons unrelated to safety or efficacy.

Listed as NCT02616146, this PHASE3 trial focuses on Contraception and remains terminated or withdrawn. Sponsored by Organon and Co, it has been updated 13 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshot~Jun 2018 – ~Feb 2019 · 8 months · monthly snapshot~Feb 2019 – ~Nov 2020 · 21 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Dec 2021 · 9 months · monthly snapshot~Dec 2021 – ~Mar 2022 · 3 months · monthly snapshot~Mar 2022 – ~Jun 2024 · 27 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

13 versions recorded
  1. Sep 2025 — Present [monthly]

    Terminated PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  4. Jun 2024 — Jul 2024 [monthly]

    Terminated PHASE3

  5. Mar 2022 — Jun 2024 [monthly]

    Terminated PHASE3

Show 8 earlier versions
  1. Dec 2021 — Mar 2022 [monthly]

    Terminated PHASE3

  2. Mar 2021 — Dec 2021 [monthly]

    Terminated PHASE3

  3. Jan 2021 — Mar 2021 [monthly]

    Terminated PHASE3

  4. Nov 2020 — Jan 2021 [monthly]

    Terminated PHASE3

  5. Feb 2019 — Nov 2020 [monthly]

    Terminated PHASE3

  6. Jun 2018 — Feb 2019 [monthly]

    Terminated PHASE3

  7. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE3

  8. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE3

    First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Organon and Co
Data source: Organon and Co

For direct contact, visit the study record on ClinicalTrials.gov .